Daraxonrasib drug nearly doubles survival in advanced pancreatic cancer, oncologist reports
By
Christopher Lieu, MD
Hot, fresh, and worth queueing round the block for.
Summary
Pancreatic cancer has extremely low survival rates (97% mortality within 5 years for metastatic cases) due to lack of effective screening and late symptom onset. The article discusses daraxonrasib, a breakthrough drug that nearly doubles survival for advanced pancreatic cancer patients, overcoming what was previously considered an 'undruggable' disease. An oncologist explains how this targeted therapy works against KRAS mutations, which are common in pancreatic cancer.
Key quotes
· 3 pulledFor patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.
Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages.
By the time a patient experiences signs, such as jaundice – a yellowing of the skin – or abdominal pain, the cancer has often already spread to other organs.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·15d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
economist.com·2d ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·10mo ago